Novel use of syndromic surveillance to monitor the impact of synthetic cannabinoid control measures on morbidity
Abstract Background Using data from syndromic surveillance, the New York City Department of Health and Mental Hygiene (DOHMH) identified an increase in the number of emergency department (ED) visits related to synthetic cannabinoids. Syndromic surveillance data were used to target community-level in...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-07-01
|
| Series: | Injury Epidemiology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s40621-019-0210-2 |
| _version_ | 1818544493711851520 |
|---|---|
| author | Michelle L. Nolan Amy Ehntholt Thomas Merrill Don Weiss Ramona Lall Denise Paone |
| author_facet | Michelle L. Nolan Amy Ehntholt Thomas Merrill Don Weiss Ramona Lall Denise Paone |
| author_sort | Michelle L. Nolan |
| collection | DOAJ |
| description | Abstract Background Using data from syndromic surveillance, the New York City Department of Health and Mental Hygiene (DOHMH) identified an increase in the number of emergency department (ED) visits related to synthetic cannabinoids. Syndromic surveillance data were used to target community-level interventions and assess the real-time impact of control measures in reducing synthetic cannabinoid (“K2”)-related morbidity. Methods From April 2015 through September 2015, DOHMH implemented 3 separate interventions to reduce K2-related morbidity by limiting the availability of K2 products. Difference-in-difference analyses compared pre- and post-intervention differences in cannabinoid-related ED visit rates between neighborhoods and controls for Interventions A and B. City-wide count data were used to compare K2-related ED visits before and after Intervention C. Results Syndromic data showed a reduction in K2-related ED visits following the 3 interventions. Respective decreases in rates of synthetic cannabinoid-related ED visits of 33 and 38% were detected at the neighborhood-level due to Interventions A and B, respectively. A decrease of 29% was calculated at the city level following Intervention C. Conclusions In addition to identifying emerging public health concerns, syndromic data can provide valuable real-time evidence on the effectiveness of public health interventions. |
| first_indexed | 2024-12-11T22:49:13Z |
| format | Article |
| id | doaj.art-739cfd1fc15c4d2b975e489606f36ffd |
| institution | Directory Open Access Journal |
| issn | 2197-1714 |
| language | English |
| last_indexed | 2024-12-11T22:49:13Z |
| publishDate | 2019-07-01 |
| publisher | BMC |
| record_format | Article |
| series | Injury Epidemiology |
| spelling | doaj.art-739cfd1fc15c4d2b975e489606f36ffd2022-12-22T00:47:30ZengBMCInjury Epidemiology2197-17142019-07-01611410.1186/s40621-019-0210-2Novel use of syndromic surveillance to monitor the impact of synthetic cannabinoid control measures on morbidityMichelle L. Nolan0Amy Ehntholt1Thomas Merrill2Don Weiss3Ramona Lall4Denise Paone5Bureau of Alcohol and Drug Use Prevention, Care, and Treatment, New York City Department of Health and Mental HygieneDepartment of Social and Behavioral Sciences, Harvard T.H. Chan School of Public HealthOffice of General Council, New York City Department of Health and Mental HygieneBureau of Communicable Diseases, New York City Department of Health and Mental HygieneBureau of Communicable Diseases, New York City Department of Health and Mental HygieneBureau of Alcohol and Drug Use Prevention, Care, and Treatment, New York City Department of Health and Mental HygieneAbstract Background Using data from syndromic surveillance, the New York City Department of Health and Mental Hygiene (DOHMH) identified an increase in the number of emergency department (ED) visits related to synthetic cannabinoids. Syndromic surveillance data were used to target community-level interventions and assess the real-time impact of control measures in reducing synthetic cannabinoid (“K2”)-related morbidity. Methods From April 2015 through September 2015, DOHMH implemented 3 separate interventions to reduce K2-related morbidity by limiting the availability of K2 products. Difference-in-difference analyses compared pre- and post-intervention differences in cannabinoid-related ED visit rates between neighborhoods and controls for Interventions A and B. City-wide count data were used to compare K2-related ED visits before and after Intervention C. Results Syndromic data showed a reduction in K2-related ED visits following the 3 interventions. Respective decreases in rates of synthetic cannabinoid-related ED visits of 33 and 38% were detected at the neighborhood-level due to Interventions A and B, respectively. A decrease of 29% was calculated at the city level following Intervention C. Conclusions In addition to identifying emerging public health concerns, syndromic data can provide valuable real-time evidence on the effectiveness of public health interventions.http://link.springer.com/article/10.1186/s40621-019-0210-2Syndromic surveillanceSynthetic cannabinoidSurveillancePublic health |
| spellingShingle | Michelle L. Nolan Amy Ehntholt Thomas Merrill Don Weiss Ramona Lall Denise Paone Novel use of syndromic surveillance to monitor the impact of synthetic cannabinoid control measures on morbidity Injury Epidemiology Syndromic surveillance Synthetic cannabinoid Surveillance Public health |
| title | Novel use of syndromic surveillance to monitor the impact of synthetic cannabinoid control measures on morbidity |
| title_full | Novel use of syndromic surveillance to monitor the impact of synthetic cannabinoid control measures on morbidity |
| title_fullStr | Novel use of syndromic surveillance to monitor the impact of synthetic cannabinoid control measures on morbidity |
| title_full_unstemmed | Novel use of syndromic surveillance to monitor the impact of synthetic cannabinoid control measures on morbidity |
| title_short | Novel use of syndromic surveillance to monitor the impact of synthetic cannabinoid control measures on morbidity |
| title_sort | novel use of syndromic surveillance to monitor the impact of synthetic cannabinoid control measures on morbidity |
| topic | Syndromic surveillance Synthetic cannabinoid Surveillance Public health |
| url | http://link.springer.com/article/10.1186/s40621-019-0210-2 |
| work_keys_str_mv | AT michellelnolan noveluseofsyndromicsurveillancetomonitortheimpactofsyntheticcannabinoidcontrolmeasuresonmorbidity AT amyehntholt noveluseofsyndromicsurveillancetomonitortheimpactofsyntheticcannabinoidcontrolmeasuresonmorbidity AT thomasmerrill noveluseofsyndromicsurveillancetomonitortheimpactofsyntheticcannabinoidcontrolmeasuresonmorbidity AT donweiss noveluseofsyndromicsurveillancetomonitortheimpactofsyntheticcannabinoidcontrolmeasuresonmorbidity AT ramonalall noveluseofsyndromicsurveillancetomonitortheimpactofsyntheticcannabinoidcontrolmeasuresonmorbidity AT denisepaone noveluseofsyndromicsurveillancetomonitortheimpactofsyntheticcannabinoidcontrolmeasuresonmorbidity |